Astorg acquires IGM Resins from Arsenal Capital Partners


Transaction summary

NEW YORK/LUXEMBOURG, May 7, 2018 – Astorg and Arsenal Capital Partners (“Arsenal”) today announced that Astorg has partnered with management and signed a definitive agreement to acquire IGM Resins (“IGM” or the “Company”), a global manufacturer and innovator of ultraviolet (“UV”) curable materials, from Arsenal. The transaction is expected to close in the second quarter of 2018 and is subject to customary closing conditions and regulatory approvals. Financial terms of the transaction were not disclosed.

Official press releases: Astorg and Arsenal

Emendo Capital acted as lead financial adviser to Astorg.

About IGM Resins

IGM specialises in the development, manufacture, and supply of products and technical services to the global UV coatings and inks market. IGM develops, produces, and distributes a full range of radiation curable materials including photoinitiators, acrylate oligomers and monomers, and additives from manufacturing facilities in Europe, Asia, and the US, supported by technical labs in each of these regions to help create next generation energy curable coatings and inks.

For additional information on IGM, visit

About Astorg

Astorg is a European private equity firm with total funds under management of over €4 billion. Astorg seeks to partner with entrepreneurial management teams to acquire European companies and create value through the provision of strategic guidance, experienced governance and adequate capital. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body enhancing its reactivity. Though not specialised, Astorg has gathered a valuable industry expertise in technology-based industrial companies, healthcare and business-to-business professional services. Astorg has offices in London, Paris, Luxembourg and Frankfurt, plus Senior Advisers based in Zurich, Paris and London.

For additional information on Astorg, visit

About Arsenal Capital Partners

Established in 2000, Arsenal Capital Partners is a leading private equity firm that specialises in investments in middle-market specialty industrials and healthcare business services companies. Since inception, Arsenal has raised institutional equity investment funds of approximately $3 billion. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience and seeks companies typically in the range of $100 - $500 million of initial enterprise value. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add.

For additional information on Arsenal, visit

Emendo Capital